Saturday, December 11, 2021 9:42:46 PM
Great post Umibe. I’ve said this before; the FDA is not some vindictive punisher for not having foreseen issues that have never been an issue. PFS has been a controversial endpoint despite how often it’s been used in Cancer trials. Scientists love to fuck with one another in some intellectual bullshit sparring match and it’s all ego. If someone looked like they had progressed on DCVax and afterward ‘everyone appears to be living longer than expected’ (Dr. Liau) and subsequent MRIs show the “recurrence” has now cleared then it was not progression in the first place. Nothing else matters. That is NOT a “failure” of PFS no matter how someone wants to spin that. No one in their right mind, including the FDA, is going to dismiss reality and claim that ‘well, you counted it as a PFS event so we have to keep it at that’… and “fuck you”. That is not going to happen. Period. PFS is meant to be a marker so that a trial doesn’t have to go on for 12 years for OS, so PFS is insignificant at this stage. One needs no “marker” of survival if the survival itself is produced. However, the SAP more than likely used the marker of “confirmed progression” as a way to back up the efficacy because it was so long, and to avoid detractors claiming it was all just coincidence somehow. Wall Street can be fooled by such bunk, scientists and clinicians not so much. And as you imply, it’s us clinicians that matter the most in the end market. I believe NWBO has the home run, know it, and are in no hurry to allow a single crack to develop and leave an opening for the obvious bullshit that will flow once TLD is announced. Look no further than the last 2 years with COVID; once the crap hits the internet the conspiracy is on…
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
